Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Keymed Biosciences, Inc. ( (HK:2162) ).
Keymed Biosciences Inc. has called its annual general meeting for June 26, 2026, in Chengdu, where shareholders will vote on adopting the audited financial statements for the year ended December 31, 2025, and re-electing two executive directors and one non-executive director, with the board empowered to set their remuneration. Investors will also decide on reappointing Ernst & Young as auditor and granting the board a general mandate to issue up to 20% of the company’s existing share capital, enhancing financial flexibility and potential fundraising capacity while reaffirming standard corporate governance practices.
The proposed share issuance mandate, which excludes rights issues, employee options, scrip dividends and existing convertible instruments, would give directors broad authority to allot new shares or convertible securities during the approved period. This framework aligns the company with common Hong Kong market practices, potentially supporting future capital-raising or strategic transactions, and signals to stakeholders that governance, oversight and funding options remain active priorities ahead of the next reporting cycle.
The most recent analyst rating on (HK:2162) stock is a Buy with a HK$92.67 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a biopharmaceutical company listed in Hong Kong that develops innovative medicines, with its operations and corporate governance overseen by a board of executive and non-executive directors. The company is subject to Hong Kong listing rules and regularly holds shareholder meetings to approve financial statements, board composition and auditor appointments.
Average Trading Volume: 2,271,230
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.24B
For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.